tiprankstipranks
Trending News
More News >
Airsculpt Technologies, Inc. (AIRS)
NASDAQ:AIRS
US Market
Advertisement

Airsculpt Technologies (AIRS) AI Stock Analysis

Compare
60 Followers

Top Page

AIRS

Airsculpt Technologies

(NASDAQ:AIRS)

Rating:50Neutral
Price Target:
$6.00
▼(-5.81% Downside)
Airsculpt Technologies faces significant financial challenges, including declining revenue and profitability issues, which heavily impact the overall score. Technical analysis shows mixed signals, and valuation metrics are weak due to a negative P/E ratio. The earnings call provides some optimism with strategic initiatives and improved capital structure, but these are not enough to offset the financial difficulties.
Positive Factors
Debt Management
The equity financing resolves the mandatory $10m debt repayment under its existing credit commitment.
Financial Performance
AIRS reiterated the 2025 guide and is tracking well versus margin targets.
Liquidity
The offering generated about $13.8m of net proceeds, which will be used to pay down debt and for general purposes.
Negative Factors
Growth Challenges
Challenges continue around organizational growth, macro pressures, and demand.
Liquidity Constraints
Liquidity remains tight with no revolver capacity and only $5.6m in cash.
Revenue Decline
Same-store revenues continue to decline at historically low levels, underscored by declining same-store cases and flat pricing.

Airsculpt Technologies (AIRS) vs. SPDR S&P 500 ETF (SPY)

Airsculpt Technologies Business Overview & Revenue Model

Company DescriptionAirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. It offers custom body contouring using its AirSculpt procedure that removes unwanted fat in a minimally invasive procedure. The company provides fat removal procedures across treatment areas; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. Its body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. As of March 10, 2022, it operated 19 centers across 15 states. AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida.
How the Company Makes MoneyAirsculpt Technologies makes money primarily through the provision of its proprietary body contouring services. The company generates revenue by performing AirSculpt procedures at its network of clinics, which are strategically located to serve a broad client base. Key revenue streams include procedure fees paid by patients seeking body sculpting treatments. Additionally, the company may benefit from partnerships with healthcare providers or aesthetic clinics that offer its services as part of their portfolio. Other factors contributing to its earnings could include patient referrals, repeat business from satisfied clients, and expansion into new geographic markets.

Airsculpt Technologies Earnings Call Summary

Earnings Call Date:Aug 01, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call reflects a mixed outlook with significant challenges in revenue and same-store sales declines due to macroeconomic factors, but also highlights improvements in capital structure, lead generation, and cost efficiency. Strategic initiatives such as new service offerings and enhanced financing options indicate potential future growth.
Q2-2025 Updates
Positive Updates
Improved Capital Structure
Completed a follow-on offering allowing the company to pay down $16 million in debt, with no borrowings on the revolving credit facility at quarter end.
Record Lead Growth
Achieved a record level of lead growth and a meaningful increase in consultation volume, aided by optimized marketing strategies.
Cost Reduction and Operational Efficiency
Implemented a cost reduction plan that improved operational efficiency and resulted in a sequential improvement of $2 million in adjusted EBITDA from Q1 2025.
Introduction of New Services
Launched a pilot of a new skin tightening procedure to 3 centers, with plans to expand the pilot in the third quarter.
Enhanced Financing and Technology Upgrades
Expanded financing options and upgraded IT systems, improving sales call routing and increasing consultation bookings.
Negative Updates
Revenue Decline
Second quarter revenue was $44 million, declining 13.7% from the second quarter of 2024, driven by lower case volume and challenging macroeconomic conditions.
Decreased Same-Store Revenue
Same-store revenue declined approximately 22% over the prior year quarter, reflecting ongoing challenges in consumer spending.
Higher Cost of Service
Cost of service as a percentage of revenue increased to 39.1% from 36.9% in the prior year period due to fixed cost components.
London Facility Challenges
London facility remains cash flow negative despite some recent performance improvements.
Company Guidance
In the second quarter of fiscal 2025, AirSculpt Technologies reported a revenue of $44 million, representing a 13.7% decline from the same period in 2024, with same-store revenue decreasing by approximately 22%. Despite this, the company noted a sequential improvement in year-over-year revenue performance and achieved record levels of lead growth and consultation volume. The average revenue per case remained stable between $12,000 and $13,000. Adjusted EBITDA for the quarter was $5.8 million, equating to a margin of 13.3%, compared to $6.9 million or a margin of 13.5% in the previous year. AirSculpt managed to pay down $16 million in debt, ending the quarter with a leverage ratio of 2.87x. Looking forward, the company maintained its annual guidance, expecting fiscal 2025 revenue between $160 million and $170 million, with adjusted EBITDA projected at $16 million to $18 million. The guidance accounts for challenging economic conditions and consumer spending uncertainties but does not anticipate an economic downturn.

Airsculpt Technologies Financial Statement Overview

Summary
Airsculpt Technologies is facing significant financial challenges, marked by declining revenues and persistent losses. While the balance sheet shows some stability, negative cash flow and profitability metrics highlight potential risks in financial health. The company needs to address operational inefficiencies and improve cash generation to enhance financial performance.
Income Statement
45
Neutral
Airsculpt Technologies shows declining revenue growth with a negative trend in profitability. The TTM data reveals a gross profit margin of 58.0%, but the company struggled with a net loss, leading to a negative net profit margin of -9.95%. The EBIT margin is also negative at -8.38%, indicating operational challenges. Although EBITDA margin is positive at 7.36%, it reflects a significant decline from previous periods, indicating pressure on core earnings.
Balance Sheet
50
Neutral
The balance sheet indicates a moderate level of stability with a debt-to-equity ratio of 0.43 in the TTM period, suggesting manageable leverage. However, the return on equity is negative due to net losses, which is a concern. The equity ratio is 38.05%, highlighting a balanced structure, yet the overall health is impacted by persistent losses.
Cash Flow
40
Negative
The cash flow statement shows a negative free cash flow in the TTM period, reflecting cash outflows that pressure liquidity. The operating cash flow to net income ratio is negative due to losses, and free cash flow to net income ratio is also negative, indicating strain in converting profits to cash. This could pose a risk if the trend continues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue165.11M180.35M195.92M168.79M133.31M62.77M
Gross Profit96.65M108.97M121.91M106.01M88.78M39.30M
EBITDA18.80M10.07M19.74M3.52M22.36M15.67M
Net Income-14.51M-8.25M-4.48M-14.68M10.55M7.58M
Balance Sheet
Total Assets198.37M210.00M204.02M200.76M200.55M179.61M
Cash, Cash Equivalents and Short-Term Investments8.19M8.23M10.26M9.62M25.35M10.38M
Total Debt85.30M105.05M99.67M107.65M100.58M49.77M
Total Liabilities107.21M130.71M120.03M129.99M117.03M55.93M
Stockholders Equity91.16M79.29M83.99M70.77M83.53M123.68M
Cash Flow
Free Cash Flow-3.88M-2.66M14.04M11.53M19.52M10.27M
Operating Cash Flow4.54M11.35M23.96M24.45M26.63M13.96M
Investing Cash Flow-10.59M-14.01M-9.92M-12.92M-7.12M-3.69M
Financing Cash Flow-1.48M630.00K-13.39M-27.26M-4.55M-5.02M

Airsculpt Technologies Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6.37
Price Trends
50DMA
5.79
Positive
100DMA
4.50
Positive
200DMA
4.83
Positive
Market Momentum
MACD
0.15
Positive
RSI
53.07
Neutral
STOCH
44.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIRS, the sentiment is Positive. The current price of 6.37 is above the 20-day moving average (MA) of 6.34, above the 50-day MA of 5.79, and above the 200-day MA of 4.83, indicating a bullish trend. The MACD of 0.15 indicates Positive momentum. The RSI at 53.07 is Neutral, neither overbought nor oversold. The STOCH value of 44.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIRS.

Airsculpt Technologies Risk Analysis

Airsculpt Technologies disclosed 74 risk factors in its most recent earnings report. Airsculpt Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Airsculpt Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
7.26%4.92%-7.34%
71
Outperform
$1.28B36.757.02%2.12%16.24%116.58%
69
Neutral
$1.73B16.6910.65%2.21%25.19%13.44%
63
Neutral
$2.91B-9.75%12.05%-432.59%
52
Neutral
$166.94M-16.16%-40.65%85.56%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
50
Neutral
$397.10M-16.47%-14.46%-315.81%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AIRS
Airsculpt Technologies
6.37
2.08
48.48%
AMED
Amedisys
100.99
3.07
3.14%
NHC
National Healthcare
111.97
-20.63
-15.56%
USPH
US Physical Therapy
84.61
2.03
2.46%
JYNT
Joint
10.70
-0.53
-4.72%
SGRY
Surgery Partners
22.82
-8.61
-27.39%

Airsculpt Technologies Corporate Events

Executive/Board Changes
Airsculpt Technologies CAO Philip Bodie Resigns
Neutral
Aug 1, 2025

On July 29, 2025, Philip Bodie resigned from his position as Chief Accounting Officer at Airsculpt Technologies, with his resignation taking effect on August 1, 2025.

Executive/Board ChangesPrivate Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
AirSculpt Technologies CFO Retirement Announcement
Neutral
Aug 1, 2025

AirSculpt Technologies reported its second quarter fiscal 2025 results, highlighting a narrowed year-over-year revenue decline and increased consumer interest despite a decrease in case volume and revenue compared to the previous year. The company is piloting new offerings such as skin tightening and expanded financing options, and it has strengthened its balance sheet by reducing debt following a common stock offering. Dennis Dean, the CFO, announced his retirement, but will remain in his role until a successor is appointed, ensuring a smooth transition.

Private Placements and FinancingBusiness Operations and Strategy
Airsculpt Technologies Completes $13.8 Million Public Offering
Positive
Jun 11, 2025

On June 9, 2025, AirSculpt Technologies entered into an underwriting agreement with Leerink Partners to sell 3,160,000 shares of common stock in a public offering, with an option for an additional 474,000 shares, which was fully exercised. The offering closed on June 11, 2025, raising approximately $13.8 million. The company plans to use the proceeds to prepay part of its outstanding debt and for general corporate purposes. Vesey Street Capital Partners, the company’s largest stockholder, purchased 1,000,000 shares. This move is expected to impact AirSculpt’s financial strategy by reducing debt and providing capital for business opportunities.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 22, 2025